The WEB-RADR 2 project seeks to build on the WEB-RADR mobile application (app) functionality delivered through the original WEB-RADR project to expand access to the platform and the reach of the information contained within it.

The project will consist of two core work streams; one focused on enhancement and adoption of the app platform to fully realise the platform’s potential, and another developing the interoperability functions that will maximise its impact. These core work streams will be coordinated and managed by an overarching governance, sustainability and project management Work Package (WP1).

Work Packages 2 and 3: The platform enhancement and technology adoption work streams will include technology development activities whilst continually reinforcing and developing user needs and requirements as the technology evolves. Functionality to the platform will be made available through application programming interfaces (APIs), meaning that third party organisations will be able to embed WEB-RADR platform functionality into their own systems, applications and websites.

Work Packages 4 and 5: The interoperability work streams will work to map regulatory terminologies to those used in healthcare (two-way mapping of SNOMED and MedDRA) using an initial mapping between a subset of key pharmacovigilance terms, and establish connectivity protocols with electronic healthcare record (EHR) databases such that adverse drug reactions (ADRs) and regulatory information can be made available in the care record.



WEB-RADR 2 has been structured to enable European Federation of Pharmaceutical Industries and Associations (EFPIA) partners to participate in all areas of the project, underlining the collaborative and inclusive approach that guides our work.


The WEB-RADR 2 project is funded by the IMI, a large-scale public-private partnership between the EU and the pharmaceutical industry association EFPIA. IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. Through its unique and innovative funding scheme, IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training.

In addition to the large biopharmaceutical companies, the participating research consortia include small- and medium-sized enterprises, patient organisations, academia and other research organisations, hospitals and public authorities.


Find out more: www.imi.europa.eu